As resistance mechanisms continue to limit the durability of RAS-targeted drugs, diving deep into these mechanisms and uncovering biomarker strategies is crucial for gaining deeper insights. Through liquid biopsy and ctDNA technologies you can discover effective biomarkers to help predict and identify resistance, enabling the development of more efficacious therapies and personalized treatment approaches.

This workshop will discuss:

• Exploring approaches to monitor and mitigate the multifaceted mechanisms underlying resistance to KRAS inhibitors for more durable treatment
• How to leverage ctDNA analysis for tracking emerging mutations and gaining insights into resistance mechanisms
• How to ensure biomarker reliability when working with heterogeneous tumors for more robust prediction and analysis